LIQOMICS provides non‑invasive liquid biopsy tests that analyze circulating tumor DNA from a simple blood draw to characterize tumors and monitor treatment response. Their ctDNA‑based assays enable precise detection of minimal residual disease in both hematologic malignancies and solid tumors, supporting early relapse identification and therapy personalization. The company also offers companion diagnostic services and custom assay development for clinical trials and drug development.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional methods of cancer monitoring often rely on invasive tissue biopsies, which can be risky, painful, and may not always capture the full picture of the disease due to tumor heterogeneity. Detecting minimal residual disease (MRD) early is crucial for timely intervention and improved patient outcomes, but current methods may lack the sensitivity needed to identify low levels of residual cancer cells.
Solution
LIQOMICS offers liquid biopsy-based assays that analyze circulating tumor DNA (ctDNA) from blood samples to provide highly sensitive genotyping and MRD detection across various cancers. Their proprietary technology enables the identification of tumor-specific mutations and the monitoring of treatment response with greater accuracy than traditional methods. The Vista family of tests covers the entire process from cell-free DNA (cfDNA) extraction and quality control to sequencing, target enrichment, and analysis with their in-house bioinformatics pipeline. LIQOMICS' approach allows for earlier detection of potential relapses and enables personalized treatment strategies based on the genetic makeup of an individual's cancer. Their LymphoVista assays are specifically designed for monitoring lymphomas and hematological cancers, detecting MRD with a sensitivity of up to 1 in 1,000,000 molecules.
Target Audience
LIQOMICS serves patients and their physicians with diagnostic testing, as well as CROs and pharmaceutical companies seeking to use MRD in clinical trial design, understand treatment responses, and identify resistance mutations.
Features
- Non-invasive liquid biopsy approach using blood samples
- Highly sensitive detection of circulating tumor DNA (ctDNA)
- Combined genotyping and MRD assays for comprehensive cancer monitoring
- Vista family of tests covering the entire process from cfDNA extraction to bioinformatics analysis
- Proprietary technology for increased sensitivity and specificity in MRD detection
- LymphoVista assays specifically designed for lymphomas and hematological cancers
- Detection sensitivity down to 1 in 1,000,000 molecules for MRD
- Ability to track multiple mutations for more accurate disease monitoring
- Platform applicable to all cancers, with expertise in lymphomas and hematological cancers
- Medical reports providing detailed genetic variant analysis and accurate MRD calculation